Apiban Tablets 2.5Mg (1 Strip = 10 Tablets)

Requires Prescription (YES/NO)

Yes

Generics

Apixaban

Used For

Stroke

How it works

Apixaban is a potent, oral, reversible, direct and highly selective active site inhibitor of factor Xa. It does not require antithrombin III for antithrombotic activity. Apixaban inhibits free and clot-bound factor Xa and prothrombinase activity. Apixaban has no direct effects on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting factor Xa, Apixaban prevents thrombin generation and thrombus development.

Dosage

Apixaban

Side Effects

Common: Haemorrhage, haematoma, epistaxis, gastrointestinal haemorrhage, rectal haemorrhage, gingival bleeding, haematuria and contusion. Uncommon: Pruritus, eye haemorrhage (including conjunctival haemorrhage), haemoptysis, haematochezia, abnormal vaginal haemorrhage, urogenital haemorrhage, occult blood positive, traumatic haemorrhage, post procedural haemorrhage and incision site haemorrhage. Rare: Brain haemorrhage and respiratory tract haemorrhage .

Drug Interactions

Inhibitors of CYP3A4 and P-gp , g. Inducers of CYP3A4 and P-gp (e.g., rifampin, carbamazepine, phenytoin, St. John’s wort) , thrombolytic agents, fibrinolytics, GPIIb/IIIa receptor antagonists, thienopyridines (e.g., clopidogrel), dipyridamole, dextran, heparin, aspirin, chronic NSAID and sulfinpyrazone.

Indication

Apixaban is indicated for: • The prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective knee or hip replacement surgery. • The prevention of stroke and systemic embolism in patients with atrial fibrillation. • The treatment of venous thromboembolic events (deep vein thrombosis [DVT], pulmonary embolism [PE]) and prevention of recurrent DVT and PE.

When not to Use

Apixaban is contraindicated in: • Hypersensitivity to the active substance or to any of the excipient of the product. • Active clinically significant bleeding including GI bleeding. • Hepatic disease associated with coagulopathy and clinically relevant bleeding risk. • Lesion or condition if considered a significant risk factor for major bleeding e.g., current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities. • Concomitant systemic treatment with HIV protease inhibitors, e.g., ritonavir.

Precaution

The safety and efficacy of Apixaban have not been studied in patients with prosthetic heart valves. Therefore, use of Apixaban is not recommended in these patients.

Warning 1

Premature discontinuation of any oral anticoagulant, including Apixaban, increases the risk of thrombotic events. To reduce this risk, consider coverage with another anticoagulant if Apixaban is discontinued for a reason other than pathological bleeding or completion of a course of therapy.

Warning 2

Epidural or spinal hematomas may occur in patients treated with Apixaban who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures.

Warning 3

Apixaban increases the risk of bleeding and can cause serious, potentially fatal, bleeding. Advise patients of signs and symptoms of blood loss and to report them immediately or go to an emergency room. Discontinue Apixaban in patients with active pathological hemorrhage .

Pregnancy category

Always consult your physician before using any medicine.

Storage (YES/NO)

Store this medicine at room temperature, away from direct light and heat.